The first approved gene therapy in the EU is scheduled to go on sale shortly at a price of €1.1M per treatment. The product, marketed… Read More »First European gene therapy scheduled to go on sale for €1.1M per treatment
A German research study of ocriplasmin treated patients has recommended that clinicians should carefully select which patients may be suitable for such treatment and that… Read More »German researchers suggest caution in selecting patients for ocriplasmin therapy in treatment of VMT
In late 2012 research by an international consortium of scientists from Asia showed that three new genes appeared to associate with primary angle closure glaucoma… Read More »GWAS studies highlight three new genes linked to glaucoma, including PLEKHA7, a gene with a putative role in the barrier function of epithelial cells
The French regulatory agency, Agence nationale de sécurité de médicament et des produits de santé (ANSM), has confirmed that it has written to Swiss pharmaceutical… Read More »French regulatory authorities seek information from Roche on Avastin use in AMD
SPK-RPE65, a novel gene therapy undergoing development for the treatment of nyctalopia, has received “breakthrough therapy designation” from the FDA. The drug’s sponsor, Spark Therapeutics,… Read More »FDA assigns breakthrough therapy designation to innovative gene therapy approach to nyctalopia (night blindness)
Collaborative research, led by the Human Genetics Centre at the University of Texas Health Science Centre in Houston, has successfully described a new genetic mutation… Read More »Newly discovered mutation may account for up to 1% of autosomal dominant retinitis pigmentosa (RP)